Furthermore, treatment with interleukin (IL)-7 and IL-15 induced a durable T stem cell memory (TSCM)-like phenotype in TCR-engineered CLTCH129>Q-specific CD4+ T cells, enabling these cells to effectively control tumors in the therapeutic setting, highlighting the clinical relevance of TCR-engineered CD4+ T cells recognizing tumor-derived NeoAg. The gene discussed is IL15; the disease is neoplasm.